96 related articles for article (PubMed ID: 23690428)
1. Complete remission after treatment with single-agent ofatumumab in a patient with high-risk leukemic mantle-cell lymphoma.
Hunstig F; Hammersen J; Kunert C; Petersen I; Merz H; Glaser A; Teichgräber U; Hochhaus A; La Rosée P
J Clin Oncol; 2013 Jul; 31(19):e312-5. PubMed ID: 23690428
[No Abstract] [Full Text] [Related]
2. Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma--a phase II trial.
Furtado M; Dyer MJ; Johnson R; Berrow M; Rule S
Br J Haematol; 2014 May; 165(4):575-8. PubMed ID: 24666179
[No Abstract] [Full Text] [Related]
3. Remarkable response to rituximab in a patient with atypical CD20(++) mantle cell lymphoma of the bone marrow leading to severe pancytopenia.
Seggewiss R; Ho AD; Kraemer A
Ann Hematol; 2004 May; 83(5):316-8. PubMed ID: 15064861
[TBL] [Abstract][Full Text] [Related]
4. Mantle cell lymphoma of the iris.
Economou MA; Kopp ED; All-Ericsson C; Seregard S
Acta Ophthalmol Scand; 2007 May; 85(3):341-3. PubMed ID: 17488468
[No Abstract] [Full Text] [Related]
5. Detection of t(12;14)(p13;q32) in a patient with IGH-CCND1 negative mantle cell lymphoma resembling ultra-high risk chronic lymphocytic leukemia.
Miao Y; Wang R; Fan L; Qiu H; Wu Y; Chen Y; Xu W; Li J
Int J Clin Exp Pathol; 2015; 8(6):7494-8. PubMed ID: 26261659
[TBL] [Abstract][Full Text] [Related]
6. [Disappearance of CD 20 after treatment with rituximab of mantle cell lymphoma].
Yoshida K; Kayano H; Shimada T; Wakao D; Takahashi N; Sugahara Y; Yagasaki F; Ito Y; Kawai N; Matsuda A; Suzuki T; Bessho M
Rinsho Ketsueki; 2003 Mar; 44(3):174-81. PubMed ID: 12722344
[TBL] [Abstract][Full Text] [Related]
7. [New data prove therapeutic superiority. MabThera in follicular and mantle cell lymphoma].
Krankenpfl J; 2002; 40(5-6):161. PubMed ID: 12271501
[No Abstract] [Full Text] [Related]
8. Complete molecular remission in refractory acute myeloid leukemia with MLL/AF9 treated with gemtuzumab ozogamicin.
Asano H; Yamamoto G; Hosoi M; Takahashi T; Hangaishi A; Kurokawa M
Leuk Res; 2010 Jul; 34(7):e152-3. PubMed ID: 20061019
[No Abstract] [Full Text] [Related]
9. Lenalidomide, as a single agent, induces complete remission in a refractory mantle cell lymphoma.
Tempescul A; Ianotto JC; Morel F; Marion V; De Braekeleer M; Berthou C
Ann Hematol; 2009 Sep; 88(9):921-2. PubMed ID: 19139889
[No Abstract] [Full Text] [Related]
10. Non-multiple lymphomatous polyposis form of mantle cell lymphoma in the gastrointestinal tract.
Tamura S; Ohkawauchi K; Yokoyama Y; Higashidani Y; Daibata M; Hiroi M; Yamamori S; Onishi S
J Gastroenterol; 2004 Oct; 39(10):995-1000. PubMed ID: 15549454
[TBL] [Abstract][Full Text] [Related]
11. RAF-1 over-expression does condition survival of patients affected by aggressive mantle cell lymphoma.
Nagy B; Galimberti S; Benedetti E; Caracciolo F; Pacini S; Vilpo J; Ferrer A; Elonen E; Franssila K; Knuutila S; Petrini M
Leuk Res; 2007 Nov; 31(11):1595-7. PubMed ID: 17572489
[No Abstract] [Full Text] [Related]
12. R-CHOP for mantle cell lymphoma.
Klumpp TR
J Clin Oncol; 2005 Sep; 23(27):6802; author reply 6802-3. PubMed ID: 16170194
[No Abstract] [Full Text] [Related]
13. Mantle cell lymphoma: clinicopathologic features and treatments.
Kauh J; Baidas SM; Ozdemirli M; Cheson BD
Oncology (Williston Park); 2003 Jun; 17(6):879-91, 896; discussion 896-8. PubMed ID: 12846128
[TBL] [Abstract][Full Text] [Related]
14. Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma.
Heinrich DA; Weinkauf M; Hutter G; Zimmermann Y; Jurinovic V; Hiddemann W; Dreyling M
Br J Haematol; 2015 Feb; 168(4):606-10. PubMed ID: 25292485
[No Abstract] [Full Text] [Related]
15. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
Böttcher S; Ritgen M; Buske S; Gesk S; Klapper W; Hoster E; Hiddemann W; Unterhalt M; Dreyling M; Siebert R; Kneba M; Pott C;
Haematologica; 2008 Apr; 93(4):551-9. PubMed ID: 18379010
[TBL] [Abstract][Full Text] [Related]
16. [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma].
Tobinai K
Gan To Kagaku Ryoho; 2002 Mar; 29(3):473-80. PubMed ID: 11915743
[TBL] [Abstract][Full Text] [Related]
17. [Antibody therapy in hematology and oncology - part 1].
Kneba M; Schrader C; Köhne H
Med Klin (Munich); 2008 Dec; 103(12):843-59. PubMed ID: 19099214
[No Abstract] [Full Text] [Related]
18. Bilateral panocular involvement with mantle-cell lymphoma.
Chappelow AV; Singh AD; Perez VL; Lichtin A; Pohlman B; Macklis R
J Clin Oncol; 2008 Mar; 26(7):1167. PubMed ID: 18309953
[No Abstract] [Full Text] [Related]
19. [Complete response by rituximab monotherapy in a patient with leukemic mantle cell lymphoma diagnosed by fluorescence in situ hybridization analysis].
Okagawa Y; Kuroda H; Ishikawa K; Yamada M; Hoki T; Abe T; Sakurai T; Fujii S; Maeda M; Fujita M; Jyomen W; Iyama S; Kato J
Gan To Kagaku Ryoho; 2012 Oct; 39(10):1547-50. PubMed ID: 23064069
[TBL] [Abstract][Full Text] [Related]
20. Treatment of mantle cell lymphoma: targeting the microenvironment.
Drach J; Seidl S; Kaufmann H
Expert Rev Anticancer Ther; 2005 Jun; 5(3):477-85. PubMed ID: 16001955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
